Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 16 tags : Phase 3 save search
Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 PatientsTopline Results Expected in the Second Quarter of 2021
Published: 2021-03-16 (Crawled : 15:00) - biospace.com/
HSTO 1 d | $0.5 67.46% 530
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -4.11%
covid phase 1 results phase 3 phase 2
Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner
Published: 2021-03-16 (Crawled : 14:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 1.12%
H: 2.4%
C: -0.41%
phase 1 phase 3 phase 2
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
Published: 2021-03-16 (Crawled : 14:00) - biospace.com/
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: -7.25%
nephropathy phase 3 enroll
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
Published: 2021-03-16 (Crawled : 13:00) - biospace.com/
GLMD | $0.3787 -0.41% 18K
|
Health Technology
|
| O: 3.89%
H: 2.67%
C: -6.15%
phase 1 trial phase 3 phase 2
Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol
Published: 2021-03-16 (Crawled : 13:00) - biospace.com/
ORMP A | $2.265 2.96% 2.87% 110K
|
Health Technology
|
| O: 1.29%
H: 4.9%
C: 2.66%
fda insulin phase 3 fda approval
New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
Published: 2021-03-16 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.76%
C: 0.57%
phase 3 skin clearance
FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
Published: 2021-03-16 (Crawled : 12:00) - biospace.com/
FGEN | $1.15 -1.71% -1.74% 1.3M
|
Health Technology
|
| O: -1.32%
H: 3.27%
C: -0.45%
treatment phase 3 duchenne
Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”
Published: 2021-03-16 (Crawled : 12:00) - biospace.com/
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 4.25%
H: 6.08%
C: 4.4%
disease alzheimer clinical trials therapy life science phase 3 trial anavex®2-73 anavex alzheimer’s alzheimer's disease alzheimer's
Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
Published: 2021-03-16 (Crawled : 11:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.26%
H: 0.04%
C: -0.33%
phase 3 ulcerative colitis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.